Reported Saturday, Arcutis' Phase 2 INTEGUMENT-INFANT Trial Shows Zoryve Cream 0.05% Achieves 49% Clear Or Almost Clear Skin And 58.3% EASI-75 In Infants With Atopic Dermatitis
Benzinga Newsdesk 7 months ago
News
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to
- Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program
- ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks
- Caregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infants
- Results from additional studies across the ZORYVE portfolio being presented in three poster presentations